Biotechnology
Excerpt from the Press Release: PLYMOUTH MEETING, Pa., Oct. 27, 2022 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster…
Read More
OTX-2002 is the First-Ever Epigenomic Controller in a New Class of Programmable mRNA Therapeutics to be Administered to Patients Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (NASDAQ: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines, today announced…
Read More
Excerpt from the Press Release: WALTHAM, Mass. and DUBLIN, Oct. 27, 2022 /PRNewswire/ — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multi-center proof-of-concept study in adult subjects to…
Read More
Positive Phase 1 Data Support Near-term Initiation of Global Phase 2 Trial Excerpt from the Press Release: CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that data from the Phase 1 ACeD (Assessment of KAN-101 in Celiac Disease) clinical trial…
Read More
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder Excerpt from the Press Release: MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received approval in Australia from…
Read More
Excerpt from the Press Release: SAN DIEGO, Oct. 14, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on oncology, announced today that it has received clearance from the US Food and Drug Administration (FDA) to commence Phase I studies with PT217, its anti-Delta-like ligand 3 (DLL3)/anti-Cluster of differentiation 47 (CD47)…
Read More
Poster on GNUV205 presented at the Immuno-Oncology Summit GNUV205 demonstrates Genuv’s “no-alpha/attenuated beta fused with anti-PD-1” strategy to reduce toxicity Excerpt from the Press Release: SEOUL, Republic of Korea & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for degenerative central nervous system diseases and advanced immuno-oncology therapeutics, unveiled a…
Read More
• No safety concerns noted in ongoing clinical trial• Study timeline remains on track Excerpt from the Press Release: MALVERN, Pa., Oct. 12, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the…
Read More
Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors. Biomea Fusion will now initiate a Phase I/Ib clinical trial (COVALENT-102) of BMF-219 as a monotherapy in patients who have unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal cancer (CRC) or pancreatic…
Read More
ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501A Protocol Supported by Clinical and Translational Data from Phase 1 Trial Indicating Deep Responses are Achievable with a Single Dose of ALLO-501A When Used with a Lymphodepletion Regimen That Includes…
Read More